Background {#Sec1}
==========

Platinum-based chemotherapy is currently the first-line treatment of choice for patients with advanced non-small-cell lung cancer (NSCLC) in the presence of wild-type epidermal growth factor receptor and non-rearranged ALK. However, no reliable predictive biomarkers of platinum resistance are currently available for routine clinical use. Breast cancer susceptibility gene 1 (BRCA1) plays a pivotal role in the repair of platinum-induced DNA damage and has been associated with cell resistance to platinum in preclinical models \[[@CR1]--[@CR3]\]. From the biological point of view, BRCA1 is involved in two main mechanisms of repair of platinum-induced DNA damage. The first one is nucleotide excision repair (NER), being the main pathway for the repair of helix-distorting DNA lesions \[[@CR4], [@CR5]\]. The second one is homologous recombination, an error-free mechanism for the repair of DNA double-strand breaks \[[@CR6]\].

In clinical retrospective series, low mRNA expression of *BRCA1* was associated with longer survival in NSCLC patients treated with cisplatin-based neoadjuvant chemotherapy \[[@CR7]\], while the clinical feasibility of prospectively assessing *BRCA1* mRNA expression was later demonstrated in a prospective phase II trial in advanced NSCLC patients \[[@CR8]\]. Despite these encouraging preliminary results, a phase III randomized trial (NCT00617656/GECP-BREC) comparing non-biomarker-directed therapy with treatment based on the mRNA expression levels of *BRCA1* and *receptor-associated protein 80 (RAP80)* was recently closed prematurely, since the interim analysis showed a detrimental effect in terms of progression free survival (PFS) in patients allocated to the experimental arm (hazard ratio \[HR\], 1.35; *p* = 0.03) \[[@CR9], [@CR10]\]. The protein RAP80 is a component of one of the BRCA1 complexes at DNA damage sites and may be essential in the assembly of the BRCA1-A complex at DNA damage sites \[[@CR11]\]. Retrospective analyses had demonstrated that *RAP80* mRNA expression could affect the predictive capacity of *BRCA1* \[[@CR8], [@CR12]\].

However, several other DNA repair components are required for the recruitment and the function of BRCA1 in DNA repair \[[@CR13], [@CR14]\]. In particular, post-translational protein modification called ubiquitination is fundamental for the assembly of effector proteins complexes. After the phosphorylation of mediator of DNA damage checkpoint 1 (MDC1), RING finger ubiquitin ligase 8 (RNF8) is recruited at DNA damage sites and creates a complex with ubiquitin conjugating enzyme 13 (UBC13). This complex induces the formation of Lys 63-linked ubiquitin chains, which are essential for the assembly of BRCA1 complexes at double-strand breaks \[[@CR15]--[@CR17]\]. Recently, HECT domain and RCC1-like domain-containing protein 2 (HERC2), which functions as an E3-ubiquitin ligase, was shown to facilitate the formation of the RNF8-UBC13 complex \[[@CR18]\] (Fig. [1](#Fig1){ref-type="fig"}). The protein HERC2 is also involved in regulating the stability of BRCA1 at DNA damage sites, since HERC2 ubiquitinates BRCA1 and targets it for degradation when BRCA1 is not in a complex with BRCA1-associated RING domain protein 1 (BARD1). The BRCA1-BARD1 heterodimer is required for BRCA1 stability, nuclear localization and E3 ligase function \[[@CR19], [@CR20]\]. This role of HERC2 is enhanced in the S-phase of the cell cycle, thus contributing to the modulation of BRCA1 function throughout the cell cycle and to the role of BRCA1 at the G2-M checkpoint \[[@CR21]\].Fig. 1The protein BRCA1 is recruited at DNA damage through a recognition mechanism implying the phosphorylation of histone H2AX and leading to the assembly of a protein complex that induces histones post-translational modification called ubiquitination. This protein complex includes the RING finger ubiquitin ligase 8 (RNF8), the conjugating enzyme 13 (UBC13) and the E3 ubiquiting ligase HECT domain-containing protein 2 (HERC2). The biological model of BRCA1 recruitment at DNA damage sites was used to select the genes to evaluate as potential predictive markers of platinum sensitivity in lung cancer

On the basis of this biological model, we hypothesized that RNF8, UBC13 and HERC2, being the main protagonists of ubiquitination process leading to BRCA1 recruitment at DNA damage sites, could modulate the predictive model based on BRCA1 expression.

Methods {#Sec2}
=======

We retrospectively analyzed a series of 71 patients diagnosed with advanced NSCLC and treated with cisplatin or carboplatin plus gemcitabine or pemetrexed in the first-line setting (Table [1](#Tab1){ref-type="table"}). Patients were selected according to first-line treatment, not including taxanes or vinca alkaloids, and availability of adequate tumor samples. No further clinical selection was performed. Radiological response was assessed using the Response Evaluation Criteria for Solid Tumor (RECIST) v 1.0 \[[@CR22]\]. Progression free survival (PFS) was calculated from the beginning of first-line treatment until demonstrated radiological progression or death from any cause. The overall survival (OS) was calculated from the start of platinum-based chemotherapy to death from any cause.Table 1Characteristics of 71 patients with advanced non-small-cell lung cancerN (%)Age median (range)63 (40--82)Gender Male54 (76) Female17 (24)ECOG PS 09 (13) 144 (62) 213 (18) No data5 (7)Smoking status Current smoker31 (44) Former smoker29 (41) Never smoked11 (15)Histology Adenocarcinoma43 (60) Squamous cell carcinoma14 (20) Large cell carcinoma14 (20)First-line treatment Cisplatin-gemcitabine32 (45) Carboplatin-gemcitabine19 (27) Cisplatin-pemetrexed10 (14) Carboplatin-pemetrexed10 (14)Second-line treatment Taxanes11 (15) EGFR TKIs22 (31) Others9 (13)Response rate Complete response0 (0) Partial response27 (38) Stable disease26 (37) Progressive disease11 (30) No data7 (10)

Paraffin-embedded tumor specimens were collected before beginning chemotherapy and patients who had previously received radiotherapy were excluded. Tumor samples were evaluated by the pathologist to ensure a minimum of 90 % of tumor cells in analyzed samples. After mRNA extraction and retro transcription, the mRNA expression levels of *BRCA1*, *RNF8*, *UBC13* and *HERC2* were quantified using real-time PCR with a comparative method, as previously described \[[@CR8]\]. mRNA levels were considered as categorical variables and dichotomized using the median value as cut-off point (Additional file [1](#MOESM1){ref-type="media"}: Supplementary Methods).

The median PFS and OS were estimated using the Kaplan-Meier method and compared with a two-sided log-rank test. Multivariate analyses were performed with the Cox regression method, with Eastern Cooperative Oncology Group (ECOG) performance status (PS) as covariate. All statistical analyses were performed using Statistical Package for Social Science (SPSS) for Windows version 17 (Chicago, IL, USA). Significance was set at *p* \< 0.05.

Results and discussion {#Sec3}
======================

The clinical features of the study population are summarized in Table [1](#Tab1){ref-type="table"}. Patients were mainly male (76 %), asymptomatic or poorly symptomatic at diagnosis (ECOG PS 0--1, 75 %), and current or former smokers (85 %). The prevalent histology was adenocarcinoma (60 %). First-line treatment was chosen according to standard clinical practice and did not include taxanes or vinca alkaloids (Table [1](#Tab1){ref-type="table"}).

The expression of each gene was successfully analyzed in 87-96 % of patients (Additional file [2](#MOESM2){ref-type="media"}: Table S1).

The median PFS for all 71 patients was 7.2 months (95 % confidence interval, CI = 5.8-8.5) and the median OS was 10.7 months (95 % CI = 9.2-12.2) (Additional file [3](#MOESM3){ref-type="media"}: Figure S1). No differences in PFS or OS were observed according to the individual expression levels of any of the four genes.

Based on our previous experience \[[@CR23]\], we then examined the potential predictive value of a two-gene model and analyzed PFS and OS according to the combination of *BRCA1* with each of the three other genes. No significant differences were observed according to the combination of *BRCA1* and *UBC13* or of *BRCA1* and *RNF8* expression levels. However, the combination of *BRCA1* and *HERC2* identified subgroups of patients with different outcomes. Reliable quantification of mRNA was available for 55 patients. Among patients expressing low levels of *BRCA1*, the median PFS was 7.4 months (95 % CI = 4.5-10.4) for those expressing low *HERC2* levels, compared to 5.9 months (95 % CI = 4.8-7.1) for patients with high *HERC2* levels (*p* = 0.01) (Fig. [2a](#Fig2){ref-type="fig"}). The median OS was 15.3 months (95 % CI = 5.5-25.8) for patients expressing low *BRCA1* and *HERC2* and 7.4 months (95%CI = 5.1-9.7) for those with low *BRCA1* but high *HERC2* levels (*p* = 0.008) (Fig. [2b](#Fig2){ref-type="fig"}). Consistently, response rates were 42.9 % in patients expressing low levels of both *BRCA1* and *HERC2* and 28.6 % in those with low *BRCA1* but high *HERC2* levels. Progressive disease was recorded as best radiological response in 23.8 % and 42.9 % of patients, respectively (Additional file [4](#MOESM4){ref-type="media"}: Table S2). In contrast, *HERC2* expression levels did not affect the outcome of patients expressing high levels of *BRCA1* (Additional file [5](#MOESM5){ref-type="media"}: Figure S2).Fig. 2(**a**) Progression-free survival and (**b**) overall survival in 30 patients with low BRCA1 levels (lower than the median value) according to HERC2 levels

To confirm the predictive value of this model, we assessed multivariate analysis and selected a more homogeneous population according to performance status (PS). Multivariate analyses showed that among patients with ECOG PS 0--1, high levels of either BRCA1 or HERC2 were associated with an increased risk of progression (HR, 1.4; 95 % CI = 1.1-4.73; *p* = 0.03) and death (HR, 3.7; 95 % CI = 1.54-9.1; *p* = 0.004) (Table [2](#Tab2){ref-type="table"}), while among patients with PS 2, no significant differences according to BRCA1 and HERC2 levels were observed.Table 2Multivariate analyses of progression-free and overall survival in 53 patients with ECOG PS 0-1Progression-free survivalHazard ratio95 % CI*P*-valuePerformance status 01.00 (referent) 11.450.62-3.410.39BRCA1/HERC2 expression Low/Low1 (referent) Other combinations1.451.10-4.730.03Overall survivalHazard ratio95 % CI*P*-valuePerformance status 01 (referent) 11.350.45-4.10.58BRCA1/HERC2 expression Low/Low1 (referent) Other combinations3.701.54 -9.100.004

The identification of predictive markers of platinum sensitivity in lung cancer can help optimize the chemotherapy approach in advanced NSCLC patients. While a defective DNA damage repair capacity is associated with increased sensitivity to platinum, the translational application of this concept is rather difficult due to the complicated interplay among DNA repair pathways \[[@CR13], [@CR14]\]. The potential predictive roles of BRCA1 and excision repair cross-complementing 1 (ERCC1) have been widely studied in NSCLC \[[@CR14], [@CR24]\]. ERCC1 is a main component of NER, and low ERCC1 protein and mRNA expression have been associated with improved outcome in platinum-treated NSCLC patients, both in early-stage and in metastatic disease \[[@CR14], [@CR24]\]. However, neither BRCA1 nor ERCC1 expression was confirmed as a predictive marker in phase III studies \[[@CR9], [@CR25]\]. Nevertheless, our knowledge of DNA repair pathways is increasing, and a pivotal role has been demonstrated for post-translational modification in the response to double-strand breaks. In particular, the proteins UBC13 and RNF8, and more recently HERC2, are known to be essential for the recruitment of BRCA1 at DNA damage sites \[[@CR13], [@CR15]--[@CR18]\].

The present study examined the hypothesis that the BRCA1 predictive model in advanced NSCLCs could be improved through the analysis of genes involved in the recruitment of BRCA1 at DNA damage sites through post-translational modifications (Fig. [1](#Fig1){ref-type="fig"}). In a retrospective, clinically homogeneous series of patients, we have demonstrated that *HERC2* mRNA expression provides additional predictive information when analyzed in conjunction with *BRCA1*. The outcome of patients expressing low *BRCA1* mRNA was significantly different according to *HERC2* mRNA expression and the median OS in patients expressing low levels of both *BRCA1* and *HERC2* was 15.3 months, which is greatly superior to that observed in unselected patients treated with platinum-based therapy (rarely exceeding 10 months) \[[@CR26]\]. Moreover, a significantly increased risk both of progression and of death was associated with high expression of either *BRCA1* or *HERC2* with Cox regression analysis.

These findings lend support to the integrated analysis of several DNA repair components, which can provide enhanced results compared to the analysis of one component alone. Moreover, our results show the important role of HERC2 in determining platinum sensitivity in patients with low *BRCA1* expression, which is consistent with its known role in the recruitment of BRCA1 at DNA damage sites \[[@CR18]\].

The main limitations of the study are its retrospective nature and the relatively small number of patients with mRNA expression data available for both *BRCA1* and *HERC2*. Due to the number of patients, we cannot draw definitive conclusions about the absence of predictive value of *UBC13* and *RNF8* in combination with *BRCA1* or of each gene when considered in isolation. In addition, mRNA expression data could not able to mirror the protein function and a validation through analyses of these markers at protein level could further increase the interest of these data. However, mRNA analysis is one of the most used surrogate marker of DNA repair capacity, taking into account the great difficulties in measuring DNA repair capacity at functional level. From the practical point of view, the need of highly experienced laboratories is one main limitation to the use of mRNA quantitative expression, while the possibility of testing more candidate markers is one strength point that could be particularly useful when studying a complex molecular pathway and the interplay of different components of the pathway.

Further development of this research would be the validation of the findings in a larger series of patients and the inclusion of a validation set of patients treated without platinum in order to test the hypothesis of a prognostic effect for the studied model. Finally the data should be confirmed prospectively.

Conclusions {#Sec4}
===========

In our study population, integrated mRNA analysis of *BRCA1* and *HERC2* shows a predictive role in advanced NSCLC patients treated with first-line platinum-based chemotherapy. The patients expressing low levels of both genes achieved better outcome to platinum, while isolated analysis of *BRCA1* does not carry predictive value. Despite the limitations of the study, our results identify a new potential predictive marker, HERC2, and further refine the BRCA1 predictive model. Importantly, our findings support and pave the way for additional biomarker analyses, potentially useful for customizing chemotherapy in lung cancer.
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